NovaBiotics, the clinical-stage anti-infectives biotechnology company, will be hosting a live Twitter Q&A between 3pm and 5pm GMT on Wednesday 29th March where CEO Dr Deborah O’Neil will provide the latest updates on the development of Lynovex and answer questions on the oral and inhaled  Lynovex® programmes. The live twitter feed is an opportunity for the CF Community to ask NovaBiotics anything they want to know about the background and continued development of Lynovex.

To ask your question, please tweet @NovaBiotics with the hashtag #Lynovex between 3pm and 5pm on Wednesday 29th March and Dr O’Neil will respond.

If you wish to submit your question privately ahead of the session, please email to info@novabiotics.co.uk with the subject ‘Lynovex CARE-CF-1 Twitter Q&A’. Responses will be posted anonymously on Novabiotics’ Twitter feed during the Q&A session.